Dr. Singh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5423 Reno Corporate Dr
Reno, NV 89511Phone+1 775-329-0873Fax+1 775-329-1026
Education & Training
SUNY Downstate Health Sciences UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003- SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1996 - 1999
Guru Govind Singh Medical CollegeClass of 1987
Certifications & Licensure
NV State Medical License 2006 - 2025
IA State Medical License 2003 - 2008
MD State Medical License 2002 - 2003- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsEffect of trimethylgallic acid esters against chronic stress-induced anxiety-like behavior and oxidative stress in mice.Mamta Sachdeva Dhingra, Sameer Dhingra, Rachna Kumria, Renu Chadha, Tejvir Singh
Pharmacological Reports. 2014-08-01 - 8 citationsMyositis - A common but underreported adverse effect of osimertinib: Case series and review of the literature.Pawel Parafianowicz, Rohee Krishan, Bryce D Beutler, Raheel Islam, Tejvir Singh
Cancer Treatment and Research Communications. 2020-01-01 - Response to: "Adverse effect of muscle damage due to osimertinib"Pawel Parafianowicz, Rohee Krishan, Bryce D Beutler, Raheel Islam, Tejvir Singh
Cancer Treatment and Research Communications. 2021-01-01
Professional Memberships
- Member
- Member
Other Languages
- Hindi, Punjabi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
